Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2017 Apr 4;17(1):22.
doi: 10.1186/s12894-017-0211-9.

Benign prostatic enlargement can be influenced by metabolic profile: results of a multicenter prospective study

Mauro Gacci  1 , Arcangelo Sebastianelli  2 , Matteo Salvi  2 , Cosimo De Nunzio  3 , Linda Vignozzi  4 , Giovanni Corona  5 , Tommaso Jaeger  2 , Tommaso Chini  2 , Giorgio Ivan Russo  6 , Mario Maggi  4 , Giuseppe Morgia  6 , Andrea Tubaro  3 , Marco Carini  2 , Sergio Serni  2
Affiliations
Multicenter Study

Benign prostatic enlargement can be influenced by metabolic profile: results of a multicenter prospective study

Mauro Gacci et al. BMC Urol. .

Abstract

Background: In last years Metabolic Syndrome (MetS) has been closely associated to Benign Prostatic Enlargement (BPE) Aim of our study is to evaluate the effect of MetS and each single MetS parameter on prostate growth in men surgically treated for BPE.

Methods: Overall, 379 men were prospectively enrolled in two tertiary referral centers. Calculated prostate volume (PV) was measured with transrectal US defining the antero-posterior (AP), the cranio-caudal (CC) and the latero-lateral (LL) diameters through the ellipsoid formula, while raw PV was calculated by suprapubic US. MetS was defined according to the NCEP-ATPIII criteria.

Results: One-hundred and forty men (36.9%) were affected by MetS. The number of MetS parameters (0 to 5) and the presence of MetS were correlated with the calculated PV. The number of MetS parameters were also directly related to increasing prostate diameters. At the binary logistic regression, MetS resulted associated to high (>60 cc) raw and calculated PV. Moreover, multivariate analysis suggested that AP diameter was mainly correlated with HDL cholesterol (r:-0.3103, p = 0.002) CC diameter with triglycerides (r:-0.191, p = 0.050) and LL diameter with systolic blood pressure (r:0.154, p = 0.044). However, at the binary logistic regression, only low HDL Cholesterol was the main determinant for the enlargement of all diameters and consequently of the whole PV.

Conclusions: Metabolic factors, specially dyslipidemia, could play a central role in the pathogenesis and progression of BPE/LUTS. Interventional studies are needed to evaluate the impact of early treatment of dyslipidemia on progression of LUTS/BPH.

Keywords: Benign prostatic enlargement; Benign prostatic hyperplasia; Dyslipidemia; Lower urinary tract symptoms; Metabolic syndrome.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Mean and 95% confidence interval of the mean of calculated prostate volume, antero-posterior (AP), cranio-caudal (CC) and latero-lateral (LL) diameters, stratified according to the number of MetS parameters
Fig. 2
Fig. 2
Scatterplot diagram of correlation between AP diameter and HDL Cholesterol, CC diameter and triglyceride, LL diameter and Systolic blood pressure
Fig. 3
Fig. 3
Odds Ratio (OR) based on based on the median prostate diameters (AP = 40 mm, CC = 45 mm, LL = 55 mm) as derived from a logistic regression model adjusted for: Age, PSA, smoking, consumption of finasteride, presence of MetS. p = Pvalue. OR = Odds ratio. LL = Lower Limit. UL = Upper Limit
See this image and copyright information in PMC

References

    1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–9. - PubMed
    1. Holtgrewe HL. Economic issues and the management of benign prostatic hyperplasia. Urology. 1995;46:23–5. doi: 10.1016/S0090-4295(99)80246-5. - DOI - PubMed
    1. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol. 2001;39:151–8. doi: 10.1159/000052430. - DOI - PubMed
    1. Vignozzi L, Rastrelli G, Corona G, Gacci M, Forti G, Maggi M. Benign prostatic hyperplasia: a new metabolic disease? J Endocrinol Invest. 2014;37(4):313–22. - PubMed
    1. Corona G, Rastrelli G, Morelli A, Vignozzi L, Mannucci E, Maggi M. Hypogonadism and metabolic syndrome. J Endocrinol Invest. 2011;34(7):557–67. - PubMed

Publication types